Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%

By Yahoo! Finance | Nov 19, 2024 at 01:17 PM EST

Eli Lilly And Co announced positive Phase 2 results for muvalaplin, a potential treatment for high Lp(a) levels linked to heart disease. The study showed significant reductions in Lp(a) levels, meeting primary and secondary endpoints, with promising safety profiles.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.